Cargando…

Immunotherapeutic Targeting of Membrane Hsp70-Expressing Tumors Using Recombinant Human Granzyme B

BACKGROUND: We have previously reported that human recombinant granzyme B (grB) mediates apoptosis in membrane heat shock protein 70 (Hsp70)-positive tumor cells in a perforin-independent manner. METHODOLOGY/PRINCIPAL FINDINGS: Optical imaging of uptake kinetics revealed co-localization of grB with...

Descripción completa

Detalles Bibliográficos
Autores principales: Gehrmann, Mathias, Stangl, Stefan, Kirschner, Andreas, Foulds, Gemma A., Sievert, Wolfgang, Doß, Brigitte T., Walch, Axel, Pockley, Alan G., Multhoff, Gabriele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400620/
https://www.ncbi.nlm.nih.gov/pubmed/22829941
http://dx.doi.org/10.1371/journal.pone.0041341
_version_ 1782238512880287744
author Gehrmann, Mathias
Stangl, Stefan
Kirschner, Andreas
Foulds, Gemma A.
Sievert, Wolfgang
Doß, Brigitte T.
Walch, Axel
Pockley, Alan G.
Multhoff, Gabriele
author_facet Gehrmann, Mathias
Stangl, Stefan
Kirschner, Andreas
Foulds, Gemma A.
Sievert, Wolfgang
Doß, Brigitte T.
Walch, Axel
Pockley, Alan G.
Multhoff, Gabriele
author_sort Gehrmann, Mathias
collection PubMed
description BACKGROUND: We have previously reported that human recombinant granzyme B (grB) mediates apoptosis in membrane heat shock protein 70 (Hsp70)-positive tumor cells in a perforin-independent manner. METHODOLOGY/PRINCIPAL FINDINGS: Optical imaging of uptake kinetics revealed co-localization of grB with recycling endosomes (Rab9/11) as early as 5 min after internalization, with late endosomes (Rab7) after 30 min, and the lysosomal compartment (LAMP1/2) after 60 to 120 min. Active caspase-3-mediated apoptosis was induced in mouse CT26 monolayer cells and 3D tumor spheroids, but not in normal mouse endothelial cells. Granzyme B selectively reduced the proportion of membrane Hsp70-positive cells in CT26 tumor spheroids. Consecutive i.v. injections of recombinant human grB into mice bearing membrane Hsp70-positive CT26 tumors resulted in significant tumor suppression, and a detailed inspection of normal mouse organs revealed that the administration of anti-tumoral concentrations of grB elicited no clinicopathological changes. CONCLUSIONS/SIGNIFICANCE: These findings support the future clinical evaluation of human grB as a potential adjuvant therapeutic agent, especially for treating immunosuppressed patients that bear membrane Hsp70-positive tumors.
format Online
Article
Text
id pubmed-3400620
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-34006202012-07-24 Immunotherapeutic Targeting of Membrane Hsp70-Expressing Tumors Using Recombinant Human Granzyme B Gehrmann, Mathias Stangl, Stefan Kirschner, Andreas Foulds, Gemma A. Sievert, Wolfgang Doß, Brigitte T. Walch, Axel Pockley, Alan G. Multhoff, Gabriele PLoS One Research Article BACKGROUND: We have previously reported that human recombinant granzyme B (grB) mediates apoptosis in membrane heat shock protein 70 (Hsp70)-positive tumor cells in a perforin-independent manner. METHODOLOGY/PRINCIPAL FINDINGS: Optical imaging of uptake kinetics revealed co-localization of grB with recycling endosomes (Rab9/11) as early as 5 min after internalization, with late endosomes (Rab7) after 30 min, and the lysosomal compartment (LAMP1/2) after 60 to 120 min. Active caspase-3-mediated apoptosis was induced in mouse CT26 monolayer cells and 3D tumor spheroids, but not in normal mouse endothelial cells. Granzyme B selectively reduced the proportion of membrane Hsp70-positive cells in CT26 tumor spheroids. Consecutive i.v. injections of recombinant human grB into mice bearing membrane Hsp70-positive CT26 tumors resulted in significant tumor suppression, and a detailed inspection of normal mouse organs revealed that the administration of anti-tumoral concentrations of grB elicited no clinicopathological changes. CONCLUSIONS/SIGNIFICANCE: These findings support the future clinical evaluation of human grB as a potential adjuvant therapeutic agent, especially for treating immunosuppressed patients that bear membrane Hsp70-positive tumors. Public Library of Science 2012-07-19 /pmc/articles/PMC3400620/ /pubmed/22829941 http://dx.doi.org/10.1371/journal.pone.0041341 Text en Gehrmann et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Gehrmann, Mathias
Stangl, Stefan
Kirschner, Andreas
Foulds, Gemma A.
Sievert, Wolfgang
Doß, Brigitte T.
Walch, Axel
Pockley, Alan G.
Multhoff, Gabriele
Immunotherapeutic Targeting of Membrane Hsp70-Expressing Tumors Using Recombinant Human Granzyme B
title Immunotherapeutic Targeting of Membrane Hsp70-Expressing Tumors Using Recombinant Human Granzyme B
title_full Immunotherapeutic Targeting of Membrane Hsp70-Expressing Tumors Using Recombinant Human Granzyme B
title_fullStr Immunotherapeutic Targeting of Membrane Hsp70-Expressing Tumors Using Recombinant Human Granzyme B
title_full_unstemmed Immunotherapeutic Targeting of Membrane Hsp70-Expressing Tumors Using Recombinant Human Granzyme B
title_short Immunotherapeutic Targeting of Membrane Hsp70-Expressing Tumors Using Recombinant Human Granzyme B
title_sort immunotherapeutic targeting of membrane hsp70-expressing tumors using recombinant human granzyme b
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3400620/
https://www.ncbi.nlm.nih.gov/pubmed/22829941
http://dx.doi.org/10.1371/journal.pone.0041341
work_keys_str_mv AT gehrmannmathias immunotherapeutictargetingofmembranehsp70expressingtumorsusingrecombinanthumangranzymeb
AT stanglstefan immunotherapeutictargetingofmembranehsp70expressingtumorsusingrecombinanthumangranzymeb
AT kirschnerandreas immunotherapeutictargetingofmembranehsp70expressingtumorsusingrecombinanthumangranzymeb
AT fouldsgemmaa immunotherapeutictargetingofmembranehsp70expressingtumorsusingrecombinanthumangranzymeb
AT sievertwolfgang immunotherapeutictargetingofmembranehsp70expressingtumorsusingrecombinanthumangranzymeb
AT doßbrigittet immunotherapeutictargetingofmembranehsp70expressingtumorsusingrecombinanthumangranzymeb
AT walchaxel immunotherapeutictargetingofmembranehsp70expressingtumorsusingrecombinanthumangranzymeb
AT pockleyalang immunotherapeutictargetingofmembranehsp70expressingtumorsusingrecombinanthumangranzymeb
AT multhoffgabriele immunotherapeutictargetingofmembranehsp70expressingtumorsusingrecombinanthumangranzymeb